11
Participants
Start Date
January 31, 2009
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
CE-224,535
one 250mg tablet, once in the morning in fasted state
CE-224,535
2x250 mg tablets, once in the morning, in fasted state
CE-224,535
4x250mg tablets, once in the morning, in fasted state
CE-224,535
2x250mg tab, once in the morning, after being fed a high fat meal
CE-224,535
4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
CE-224,535
4x125 mg IR once in the morning after being fed a high fat meal
CE 224,535
2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
CE 224,535
2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
Pfizer Investigational Site, New Haven
Lead Sponsor
Pfizer
INDUSTRY